Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorisation Application (MAA) of Elocta((TM)) (rFVIIIFc), a recombinant factor VIII Fc fusion protein product candidate for the treatment of haemophilia A. The validation of the MAA initiates the EMA's review process. Elocta is the European trade name for rFVIIIFc, also known as Eloctate((TM)) [Antihemophilic Factor (Recombinant), Fc Fusion Protein] in the U.S., Canada, and Australia, where it is approved for the treatment of hemophilia A. Eloctate is the first recombinant clotting factor VIII therapy with prolonged circulation to provide protection from bleeding episodes with the potential for an extended interval between prophylactic injections. "The validation of Elocta's application by the EMA is an important step toward bringing this innovative treatment to people with haemophilia A in Europe," said Douglas E. Williams, Ph.D., executive vice president of Research and Development at Biogen Idec. "Elocta has the potential to protect against bleeding episodes while helping to address the challenge of frequent injections." The regulatory application included results from the pivotal, Phase 3 clinical study, A-LONG that examined the efficacy, safety and pharmacokinetics of rFVIIIFc in males 12 years of age and older with severe haemophilia A and from the Phase 3 clinical study, Kids A-LONG that evaluated the efficacy and safety of rFVIIIFc in children with haemophilia A under 12 years of age. Biogen Idec and Sobi are collaborators in the development and commercialization of Eloctate/Elocta for haemophilia A. Sobi has an opt-in right to take over final development and commercialisation of Elocta for the Sobi territories (Europe, North Africa, Russia and most Middle Eastern markets). Biogen Idec leads development for Eloctate/Elocta, has manufacturing rights, and has commercialisation rights in North America and all other regions in the world excluding the Sobi territories. "Sobi and Biogen Idec are committed to addressing significant medical needs in the global haemophilia community," said Birgitte Volck, M.D., Ph.D., senior vice president of Development and Chief Medical Officer of Sobi. "We're working collaboratively to deliver innovative medicines that have the potential to change the way haemophilia A is treated." --- About Haemophilia A Haemophilia A is a rare, chronic, genetic disorder in which the ability of a person's blood to clot is impaired, due to missing or reduced levels of a protein known as factor VIII. People with haemophilia A experience bleeding episodes that may cause pain, irreversible joint damage and life-threatening hemorrhages. The World Federation of Hemophilia global survey conducted in 2012 estimates that approximately 142,000 people worldwide are identified as living with haemophilia A. About the A-LONG Clinical Study The Phase 3 A-LONG clinical study was an open-label, multi-center study involving 165 previously treated males 12 years of age and older with severe haemophilia A. The study evaluated individualized and weekly prophylaxis to reduce or prevent bleeding episodes, and on-demand dosing to treat bleeding episodes. In the individualized arm, each study participant started on a twice- weekly dosing regimen. Participants' pharmacokinetic parameters were used to guide adjustments to dosing interval (every three to five days), and dose (25 to 65 IU/kg) to target a minimum factor VIII level of 1 to 3 IU/dL or higher as needed to prevent and control breakthrough bleeding episodes. In the study, the dose in the weekly prophylaxis arm was 65 IU/ kg/week. About the Kids A-LONG Clinical Study The Kids A-LONG study is the first clinical study to evaluate an investigational haemophilia therapy with a prolonged half-life in children younger than 12 years of age. The study was a global, open-label, multi-center Phase 3 study involving 71 boys with severe haemophilia A with at least 50 prior exposure days to factor VIII therapies. Participants in both the A-LONG and Kids A-LONG clinical trials were able to enroll in ASPIRE, a long-term extension clinical study evaluating the safety and efficacy of Eloctate. For more information about these studies, please visit www.biogenidec.com. About Elocta Elocta is an investigational, recombinant clotting factor therapy developed for haemophilia A by fusing factor VIII to the Fc portion of immunoglobulin G subclass 1, or IgG1 (a protein commonly found in the body). It is believed that this enables Elocta to use a naturally occurring pathway to prolong the time therapy remains in the body. While Fc fusion has been used for more than 15 years, Biogen Idec is the only company to apply it to the treatment of haemophilia. About Biogen Idec Through cutting-edge science and medicine, Biogen Idec discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. Founded in 1978, Biogen Idec is the world's oldest independent biotechnology company and patients worldwide benefit from its leading multiple sclerosis and innovative haemophilia therapies. For product labeling, press releases and additional information about the Company, please visit www.biogenidec.com. About Sobi Sobi is an international specialty healthcare company dedicated to rare diseases. Sobi's mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Inflammation and Genetic diseases, with two late stage biological development projects within Haemophilia. Sobi also markets a portfolio of specialty and rare disease products for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2013, Sobi had total revenues of SEK 2.2 billion (€253 M) and about 550 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com. For more information please contact Sobi Media Contact: Investor Relations contact: Oskar Bosson Jörgen Winroth +46 70 410 71 80 +1 347-224-0819, +1 212-579-0506, +46 8 697 2135 oskar.bosson@sobi.com jorgen.winroth@sobi.com Biogen Idec Media Contact: Investor Relations Contact: Lee-Ann Murphy Ben Strain +1-781-464-3260 +1-781-464-2442 public.affairs@biogenidec.com IR@biogenidec.com [HUG#1867719]
Biogen Idec and Sobi announce European Medicines Agency
Top 10 Most Recent News Articles
Apani Adds Kelsun Assets to Its Natural Fiber Platform
A materials deal with more chemistry than chest-thumping Seaweed and cotton have landed under one roof, which is a lot more interesting than another apparel brand slapping a green label on ordinary fabric. Apani said November 17 it acquired the assets of Keel Labs, bringing Keel's seaweed-based Kelsun fiber alongside Apani's enhanced cotton-cellulose filament technology....
Continue Reading
Snowrise Targets the Blind Spots in CPG Sales Data
A sales total can look healthy while the floorboards are quietly rotting underneath it. That is the uncomfortable CPG problem Snowrise is aiming at: brands know what moved last quarter, but often cannot identify which stores, channels, communities, or promotions actually created the result. Plenty of management teams still steer by topline revenue, net distribution gains,...
Continue Reading
illumine Targets Childcare Chain Control and Risk Gaps
Expansion Gets Messy Before It Gets Impressive Childcare operators do not usually stumble because they forgot how to care for children; they stumble because the back office fractures as the network grows. One center handles fees one way, another lets enrollment leads work a different funnel, and headquarters discovers too late that its reports are arguing with each other....
Continue Reading
Vuzix Bets on Lightweight Color Glasses for OEM Partners
Forty grams is where this story gets interesting, because faces are ruthless product testers. People will tolerate plenty of clever technology right up until it pinches, looks goofy, leaks light, or makes them feel like they are wearing a science project. Vuzix is trying to clear that hurdle with Ultralite Color, a full-color AI eyewear reference platform built for OEM...
Continue Reading
Red Cat Stock Drama: Revenue Targets and Legal Waves
Red Cat's Revenue Predictions Crash and Burn Sitting there on August 6, 2026, Red Cat Holdings had everyone believing they were on a fast track to hitting a hefty revenue target: $150–$180 million for FY2026. CEO Jeffrey Thompson didn't mince words, boasting confidence like a captain before a storm. Fast forward three months, and they're waving the white flag, tossing...
Continue Reading
Mantle's Japan Listing Puts $MNT Through a Real Test
Japan's crypto gatekeepers just handed Mantle a key, not a crown. The November 18 listing of $MNT on GMO Coin is a meaningful operational win because getting onto a Japanese centralized exchange is not the usual loose-change exercise seen in friendlier jurisdictions. Mantle cleared a review process involving GMO Coin and the Japan Virtual and Crypto Assets Exchange...
Continue Reading
Markel Elevates War Risk Expertise in London Market
A Specialty Desk Gets Its Own Weather Vane War and political violence underwriting is not a corner of insurance where a fancy title change can be shrugged off. The ground shifts under the policyholder, the broker and the carrier without much warning, and a bad call can sit on a book for years. Markel Insurance has named Chloe Gordge Director of War and Political Violence...
Continue Reading
Legato Frames Put Tiny AI to a Real-World Hearing Test
A hearing aid that never enters the ear is a deceptively brutal product challenge. It has to hear speech through a mess of restaurant clatter, traffic, wind and ordinary human commotion; it has to run all day; and, crucially, it cannot look like a medical concession somebody reluctantly straps on. Legato Frames are aiming right at that knot, with femtoAI providing the...
Continue Reading
MacDill Mold Case Puts Privatized Housing on Notice
Four hundred fifty-four people are a hard number to shrug off. The expanded civil case over alleged toxic mold conditions at MacDill Air Force Base now covers 105 military families, up from 39 households when it was filed in September 2025. Their complaint against The Michaels Organization and affiliated entities may be the largest known military-housing lawsuit in the...
Continue Reading
ETCO Targets the Unflashy Weak Link in Battery Storage
A battery cabinet can look impressive right up until one lousy connection becomes the problem nobody budgeted for. ETCO Incorporated’s new lineup of standard and custom connectors and terminals goes after that unglamorous part of battery energy storage systems: the physical handoff points carrying power, grounding equipment, and tying auxiliary components together. It...
Continue ReadingTop 5 Most Recently Viewed Articles
AEA Private Debt's Strategic Investment in Weller Metalworks
Let's cut to the chase: AEA Private Debt is making some serious waves in the middle market with its latest move as the Sole Provider of mezzanine notes for Weller Metalworks' acquisition of DROP Sprockets, Inc. This isn’t just another deal; it’s a calculated step in an increasingly competitive landscape where metal fabrication firms are vying for supremacy. Weller...
Continue Reading
Medication Management Partners Continues to Excel in Senior Care
Medication Management Partners Earns Prestigious Recognition In recent news, Medication Management Partners (MMP), a leading long-term care pharmacy, proudly announces its place on the Inc. 5000 list of fastest-growing private companies in America for the seventh consecutive year. This achievement signifies the company’s steady growth and innovative practices in the...
Continue Reading
AlphaGen Unveils Major Expansion Plans for Power Generation
AlphaGen's Ambitious 450 MW Power Generation Initiative Alpha Generation, LLC ("AlphaGen"), based in Stamford, Conn., is taking a significant step towards meeting the escalating demand for reliable electric power across the nation. With plans to add approximately 450 megawatts (MW) of additional electric generation at four existing power stations, AlphaGen aims to bolster...
Continue Reading
STAT Secures a Loeb Award for Outstanding Reporting on Opioids
STAT Achieves Recognition for Vital Reporting STAT addiction reporter Lev Facher has been honored with a 2025 Loeb Award for his exceptional work in explanatory reporting. This award, regarded as the pinnacle of accomplishment in business and financial journalism, recognizes Facher's six-part series titled "The War on Recovery." The compelling series sheds light on the...
Continue Reading
Investigation into Nomura Holdings, Inc. Sparks Investor Concerns
Introduction to the Investigation of Nomura Holdings, Inc. Pomerantz LLP is currently conducting an investigation focused on claims made on behalf of investors of Nomura Holdings, Inc. (NYSE: NMR). The essence of this investigation revolves around whether Nomura and some of its key officers or directors may have engaged in securities fraud or other illicit business...
Continue Reading